Axsome Therapeutics Stock News

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

Amid the 2021 Biotech Bear market, most bio-stocks are trading at a deep bargain to their intrinsic value.Adding insult to injury, Axsome Therapeutics is hit by a delay in FDA decision due to COVID.

These stocks could rebound nicely in the new year.

During the last session, Axsome Therapeutics Inc. (NASDAQ:AXSM)s traded shares were 0.74 million, with the beta value of the company hitting 2.21. At the end of the trading day, the stocks price was $35.30, reflecting an intraday gain of 5.34% or $1.79. The 52-week high for the AXSM share is $87.24, that puts it down Axsome Therapeutics Inc. (NASDAQ: AXSM) Is Decrease -54.10%, So Heres What We Can Expect On The Upswing Read More »

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have earned an average rating of Buy from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 year target price []

Related Stocks: PAYA , STL , CW , SI , CHK , PYCR , ACHC , SAVE , NOV , SBNY , FL , BLI , AXSM ,

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have been assigned an average rating of Buy from the thirteen analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price target among analysts that []

Analysts forecast that Axsome Therapeutics, Inc. (NASDAQ:AXSM) will announce earnings of ($0.99) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Axsome Therapeutics earnings, with the lowest EPS estimate coming in at ($1.13) and the highest estimate coming in at ($0.87). Axsome Therapeutics reported earnings per share of ($0.78) during []

We have more clarity on the FDA-cited deficiencies. These are CMC issues and management thinks are easily addressable.

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

Marketwide headwinds pushed this promising biotech stock lower this week.

Marketwide headwinds pushed this promising biotech stock lower this week.

All three of these stocks could rise over 100% once stock-market sentiment falls in line with the opinions of investment-bank analysts.

Goldman Sachs Group Inc. lowered its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 70.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,028 shares of the companys stock after selling 100,662 shares during the period. Goldman Sachs Group Inc. owned []

Both of these companies have potential catalysts on the way.